Pharmacological Management of Neuropathic Pain after Radiotherapy in Head and Neck Cancer Patients: A Systematic Review

Abstract

Background: Neuropathic pain (NP) in head and neck cancer (HNC) patients represents a treatment challenge. Most studies investigating drugs against NP are conducted in patients suffering with diabetic neuropathy or postherpetic neuralgia, while data are limited in cancer pain management. Additionally, regarding cancer therapy-related NP, most of the studies do not focus on HNC patients. The aim of this review is to identify the studies on systematically administered medication for NP management that included HNC patients under radiotherapy. Methods: A systematic literature search was performed, following the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines, in PubMed, Cochrane Library, Web of Science and ClinicalTrials.gov on 30 October 2021. The medical subject heading (MeSH) terms were (“head and neck cancer” OR “tumor”) AND “neuropathic pain” AND “medication” AND “radiotherapy.” The Cochrane Collaboration tool was used for quality assessment. Results: The search identified 432 articles. Three more articles were identified after searching the reference lists of the retrieved articles. A total of 10 articles met the eligibility inclusion criteria and were included in this review; 6 on gabapentin, 1 on pregabalin, 1 on nortriptyline, 1 on methadone, and 1 on ketamine. Statistically significant results in pain reduction compared to placebo or standard pain medication were found in the studies on pregabalin (p = 0.003), methadone (p = 0.03), ketamine (p = 0.012), and in two out of six gabapentin studies (p < 0.004). Two of the studies (both concerning gabapentin) had no comparison arm. Conclusions: Treatments including pregabalin, methadone, ketamine, and gabapentin were found to provide pain relief against HNC NP. While there is a plethora of pharmacological treatments available for the management of NP, only a few studies have been conducted regarding the pharmacological management of therapy-related NP in HNC patients. More studies should be conducted regarding the pharmacological approaches in HNC therapy-related NP so that specific treatment algorithms can be developed.

Management of Acute Cancer Pain in Asia: An Expert Opinion on the Role of Tramadol/Dexketoprofen Fixed-Dose Combination

“…Neuropathic cancer pain results from injury or compression of the nerves or other structures of the nervous system. It is caused by direct damage to the nerves from a tumor or through post-treatment neuralgia following surgery, radiotherapy and chemotherapy [ 9 , 16 , 21 , 22 ]. Regardless of its underlying mechanisms, cancer pain can be broadly categorized as acute or chronic.…”

“…Chronic cancer pain is most often due to the tumor itself but can also result from post-treatment neuralgia [ 22 , 23 ].…”

Challenges and Opportunities in Developing Tailored Pain Management Strategies for Liver Patients

“…These meetings serve as a forum for analyzing cases, exchanging perspectives, and making decisions together. By engaging in a collaborative process of generating ideas, healthcare providers can enhance treatment plans, tackle difficulties, and coordinate actions to maximize pain management for patients with liver conditions [ 28 ].…”

“…Adopting a patient-centered approach, which involves individuals actively engaging in decision-making and goal-setting, catalyzes improving communication. By working together to create care plans that align with the patient's preferences, values, and lifestyle, we can ensure that the interventions are well-suited to the individual's specific requirements [ 28 ]. Enabling patients to participate in their pain management process actively enhances their sense of control and encourages them to follow the entire care plan.…”

Relationship between breakthrough cancer pain, background cancer pain and analgesic treatment – case series and review of the literature

“…We report the cases of two patients with neuropathic pain (cases 2 and 3). In case 3, the occurrence of such pain, especially after the second cycle of radiotherapy, 51 may have been responsible for the rapid escalation of adjuvants and opioid doses, which ultimately did not lead to an improvement in pain control. 52 , 53 …”